Thymosin Alpha-1 Peptide: The 28-Residue Thymic Signal, Explained
Written bySpartan Research Team

Thymosin alpha-1 is a 28-amino-acid peptide first isolated from calf thymus in 1977. In mice it activates dendritic cells through Toll-like receptor signaling. A synthetic copy is called thymalfasin, and research-grade thymosin alpha-1 is a separate compound sold for laboratory use only.
- It came out of the thymus. Goldstein’s group isolated it from calf thymus and sequenced its 28 residues (Goldstein et al., 1977).
- It works through innate immune cells in mice. Thymosin alpha-1 drove dendritic cells to mature and signal via Toll-like receptors (Romani et al., 2004).
- It isn’t thymosin beta-4. Same family name, different molecule: beta-4 is 43 residues long and binds actin.
- The synthetic copy has its own regulatory history. Thymalfasin holds US orphan drug designations, which aren’t a marketing approval.
What is thymosin alpha-1?
Thymosin alpha-1 is a 28-amino-acid peptide that the thymus gland makes. The thymus is where T cells mature, and the peptide was found while researchers were trying to work out which thymic molecules did the instructing.
Allan Goldstein’s laboratory isolated it from calf thymus in 1977, purified it from a crude thymic extract known as fraction 5, and sequenced all 28 residues (Goldstein et al., 1977). The authors described it as immunologically active and proposed a role in the regulation and differentiation of T cells.
The sequence is highly acidic, rich in glutamate and aspartate, and its first residue carries an acetyl group. That gives it a calculated mass of about 3,108 Da, a useful number for identity testing later.
Thymosin alpha-1 fact file
| Feature | Thymosin alpha-1 |
| Other names | Ta1, thymalfasin (synthetic copy) |
| Length | 28 amino acids, N-terminal acetyl group |
| Approximate mass | 3,108 Da (calculated) |
| Source | Isolated from calf thymus, 1977 |
| Main research areas | Dendritic cell activation, Toll-like receptor signaling in mice |
| Regulatory status | Synthetic copy (thymalfasin) holds US orphan designations; research-grade material is a separate compound |
How the thymus signal was found
Does the thymus make hormones? Chasing that 1960s question, Goldstein and colleagues took calf thymus, extracted it, and separated the mixture into fractions. Fraction 5 was the one that held activity in the immune assays.
It was still a soup of dozens of peptides. Working through it, the team pulled out one that held the activity and worked out its full sequence (Goldstein et al., 1977). They named it thymosin alpha-1, the first of a family that would also come to include thymosin beta-4.
The two thymosins share a name and a source, and almost nothing else.
Thymosin alpha-1 vs thymosin beta-4

The two thymosins
| Feature | Thymosin alpha-1 | Thymosin beta-4 |
| Length | 28 amino acids | 43 amino acids |
| Approximate mass | 3,108 Da | 4,963 Da |
| Best-known role | Immune cell signaling | Binding actin, the cell’s structural protein |
| Main animal models | Dendritic cells and fungal challenge in mice | Rat skin wound models |
| Research-market name | Thymosin alpha-1, Ta1 | TB-500 (sometimes only a fragment) |
Thymosin beta-4 is the major actin-sequestering molecule in cells, which is why its research runs toward wound closure and cell movement (Goldstein et al., 2005). Thymosin alpha-1 has no actin role; its literature is about immune cells.
The two are easy to tell apart on a mass spectrum, 3,108 Da against 4,963 Da. The thymosin beta 4 guide covers the full-length protein, and the TB-500 guide explains why some vials sold under that name hold only a seven-residue fragment.
What does thymosin alpha-1 do in mice?
The best-characterized mechanism comes from a 2004 mouse study. Thymosin alpha-1 drove dendritic cells, the immune system’s sentinel cells, to mature and produce interleukin-12 when they encountered a fungus (Romani et al., 2004).
That effect ran through Toll-like receptor signaling and depended on the adaptor protein MyD88, with the p38 MAP kinase and NF-kappa-B pathway downstream (Romani et al., 2004). In mice that had received a bone-marrow transplant, the peptide also promoted a T-helper-1 type response and faster recovery of myeloid cells.
That study stands out on two counts. It names a receptor family and an adaptor, which most peptide studies don’t, and it ties the molecular readout to an outcome in live mice.
What the thymosin alpha-1 literature looks like
Thymosin alpha-1 differs from most peptides on a research catalog in one way: much of its published record is clinical work on the synthetic form. A 2020 review gathers that literature in one place (Dominari et al., 2020).
This guide doesn’t report those clinical outcomes. It stays with the laboratory and animal work, which is thinner than the clinical record and is where research-grade material belongs.
Regulatory history
Thymalfasin, the synthetic copy of thymosin alpha-1, has received US orphan drug designations, which recognize a candidate for a rare condition and are distinct from a marketing approval (SciClone, 2006).
Research-grade thymosin alpha-1 is a separate research compound rather than thymalfasin, and isn’t for human use.
Questions to ask of a thymosin alpha-1 study
- Which thymosin? Alpha-1 and beta-4 are routinely confused in secondary sources. Check the sequence or the mass.
- Cells, mice or people? Dendritic-cell work in culture, mouse challenge models and clinical trials answer different questions, and the last doesn’t apply to research-grade material.
- Which readout? Interleukin-12, Toll-like receptor signaling and T-helper-1 polarization are three separate findings.
- Was the peptide acetylated? The natural molecule carries an N-terminal acetyl group; a synthetic lot without it is a different compound.
Where it sits beside BPC-157
Thymosin alpha-1 appears in research designs beside BPC-157, the gastric pentadecapeptide studied in rat injury models, because the two cover different ground: one an immune signal, the other a tissue-repair model compound. The BPC-157 peptide guide walks through the rat literature, and Spartan sells the pair as a two-compound research stack.
Verifying a thymosin alpha-1 lot
- Identity by mass spectrometry, expecting a mass near 3,108 Da for the acetylated 28-residue peptide. A mass near 3,066 Da would mean the acetyl group is missing.
- Purity by HPLC, reported as the main peak’s share.
- A lot number printed on the certificate that agrees with the label.
Spartan’s thymosin alpha 1 peptide ships with a lot-specific certificate, and the published certificates of analysis can be reviewed before ordering. The peptide arrives freeze-dried; unopened vials belong in the cold and the dark at the temperature the certificate states, with the lot logged against each experiment.
Thymosin alpha-1 in brief
Thymosin alpha-1 is a 28-residue, acetylated peptide from the thymus, sequenced in 1977 and studied in mice for its action on dendritic cells through Toll-like receptors. Its synthetic twin, thymalfasin, has a regulatory history of its own, so the research-grade vial is a different thing and should be read as one.
Thymosin alpha-1 FAQ
What is thymosin alpha-1?
Thymosin alpha-1 is a 28-amino-acid peptide first isolated from calf thymus in 1977. In mice it activates dendritic cells through Toll-like receptor signaling. Research-grade thymosin alpha-1 is sold for laboratory use only.
What is Ta1 peptide?
Ta1 is shorthand for thymosin alpha-1, the same 28-residue thymic peptide. The synthetic copy of the same sequence is called thymalfasin.
What’s the difference between thymosin alpha-1 and thymosin beta-4?
They share a name and a source and little else. Alpha-1 is 28 residues (about 3,108 Da) and studied for immune cell signaling; beta-4 is 43 residues (about 4,963 Da), binds actin, and is studied in rat wound models.
What does thymosin alpha-1 do in mice?
In a 2004 study, it drove dendritic cells to mature and produce interleukin-12 through Toll-like receptor and MyD88 signaling, and promoted a T-helper-1 type response in transplanted mice given a fungal challenge.
Is thymosin alpha-1 FDA approved?
No. Its synthetic copy, thymalfasin, holds US orphan drug designations, which aren’t a marketing approval. Research-grade thymosin alpha-1 is a laboratory compound, separate from thymalfasin, and sold for research use only.
Is thymosin alpha-1 the same as TB-500?
No. TB-500 is a market name tied to thymosin beta-4, a different 43-residue peptide. Thymosin alpha-1 is 28 residues long and has no actin-binding role.
How is a thymosin alpha-1 lot verified?
By mass spectrometry, expecting about 3,108 Da for the acetylated peptide, plus HPLC purity and a certificate lot number that agrees with the label. A mass about 42 Da lower means the acetyl group is missing.
Research use disclaimer. All content published by Spartan Peptides is for educational and research purposes only. It is not medical advice and is not a recommendation for human use. Products sold on this site are research compounds intended for laboratory and in vitro applications only.
Written by the Spartan Research Team
Our team of peptide researchers and biochemists reviews every article for scientific accuracy. Learn more about our team →